# Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

> **NCT02472977** · PHASE1,PHASE2 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 61 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** Ulocuplumab
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02472977
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-07-13
- **Primary completion:** 2017-01-27
- **Final completion:** 2017-01-27
- **Target enrollment:** 61 (ACTUAL)
- **Why stopped:** Trial terminated because of lack of efficacy in the short term acute phase
- **Last updated:** 2018-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02472977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02472977, "Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02472977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*